Off-label indications for atypical antipsychotics: A systematic review

被引：34

作者：

Fountoulakis K.N. ^{[1
]}

Nimatoudis I. ^{[1
]}

Iacovides A. ^{[1
]}

Kaprinis G. ^{[1
]}

机构：

[1] 3rd Department of Psychiatry, Aristotle University of Thessaloniki, Thessaloniki

来源：

Annals of General Hospital Psychiatry | / 3卷 / 1期

关键词：

Atypical antipsychotics; Depression; OCD; Off-label prescription; Personality disorders; Pervasive developmental disorder; Pharmacotherapy; Stuttering; Tourette's syndrome;

D O I：

10.1186/1475-2832-3-4

中图分类号：

学科分类号：

摘要：

Introduction: With the introduction of newer atypical antipsychotic agents, a question emerged, concerning their use as complementary pharmacotherapy or even as monotherapy in mental disorders other than psychosis. Material and method: MEDLINE was searched with the combination of each one of the key words: risperidone, olanzapine and quetiapine with key words that refered to every DSM-IV diagnosis other than schizophrenia and other psychotic disorders, bipolar disorder and dementia and memory disorders. All papers were scored on the basis of the JADAD index. Results: The search returned 483 papers. The selection process restricted the sample to 59 papers concerning Risperidone, 37 concerning Olanzapine and 4 concerning Quetiapine (100 in total). Ten papers (7 concerning Risperidone and 3 concerning Olanzapine) had JADAD index above 2. Data suggest that further research would be of value concerning the use of risperidone in the treatment of refractory OCD, Pervasive Developmental disorder, stuttering and Tourette's syndrome, and the use of olanzapine for the treatment of refractory depression and borderline personality disorder. Discussion: Data on the off-label usefulness of newer atypical antipsychotics are limited, but positive cues suggest that further research may provide with sufficient hard data to warrant the use of these agents in a broad spectrum of psychiatric disorders, either as monotherapy, or as an augmentation strategy. © 2004 Fountoulakis et al; licensee BioMed Central Ltd.

引用

页数：10

共 121 条

[1]

Potenza M.N., McDougle C.J., Potential of Atypical Antipsychotics in the Treatment of NonPsychotic Disorders, CNS Drugs, 9, pp. 213-232, (1998)

[2]

Schweitzer I., Does Risperidone have a place in the treatment of nonschizophrenic patients?, International Clinical Psychopharmacology, pp. 1-19, (2001)

[3]

Leysen J.E., Janssen P.M., Megens A.A., Schotte A., Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity, Journal of Clinical Psychiatry, 55, SUPPL., pp. 5-12, (1994)

[4]

Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Arnot W., A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients, Journal of Clinical Psychopharmacology, pp. 25-40, (1993)

[5]

Marder S.R., Meilbach R.C., Risperidone in the treatment of Schizophrenia, American Journal of Psychiatry, 151, pp. 825-835, (1994)

[6]

Kapur S., Seeman P., Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis, American Journal of Psychiatry, 158, pp. 360-369, (2001)

[7]

Kapur S., Zipursky R.B., Remington G., Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia, American Journal of Psychiatry, 156, pp. 286-293, (1999)

[8]

Jadad A., Moore A., Carroll D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., McQuay H.J., Assessing the quality of reports of randomized clinical trials: Is blinding necessary?, Controlled Clinical Trials, 17, pp. 1-12, (1996)

[9]

Ad-Dab'bagh Y., Greenfield B., Milne-Smith J., Freedman H., Inpatient treatment of severe disruptive behaviour disorders with risperidone and milieu therapy, Can. J. Psychiatry, 45, pp. 376-382, (2000)

[10]

Andrade C., Risperidone may worsen fluoxetine-treated OCD, J. Clin. Psychiatry, 59, pp. 255-256, (1998)

← 1 2 3 4 5 6 7 8 9 10 →